JPMorgan Chase & Co. Lowers Theravance Biopharma (NASDAQ:TBPH) to Underweight

JPMorgan Chase & Co. lowered shares of Theravance Biopharma (NASDAQ:TBPH) from an overweight rating to an underweight rating in a research note issued to investors on Wednesday morning, Analyst Price Targets reports. They currently have $7.00 price target on the biopharmaceutical company’s stock.

TBPH has been the subject of a number of other research reports. HC Wainwright lowered their target price on Theravance Biopharma from $32.00 to $21.00 and set a buy rating for the company in a report on Tuesday, August 24th. Robert W. Baird lowered their target price on Theravance Biopharma from $20.00 to $10.00 and set a neutral rating for the company in a report on Tuesday, August 24th. Cowen cut Theravance Biopharma from an outperform rating to a market perform rating and lowered their target price for the stock from $42.00 to $14.00 in a report on Tuesday, August 24th. Citigroup lowered their target price on Theravance Biopharma from $20.00 to $14.00 and set an underperform rating for the company in a report on Tuesday, August 24th. Finally, Needham & Company LLC reduced their price objective on shares of Theravance Biopharma from $32.00 to $18.00 and set a buy rating for the company in a research note on Tuesday, August 24th. Four analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Hold and an average target price of $12.70.

TBPH opened at $7.11 on Wednesday. Theravance Biopharma has a 12 month low of $6.10 and a 12 month high of $22.74. The company has a fifty day simple moving average of $11.50 and a 200 day simple moving average of $16.22. The stock has a market cap of $522.37 million, a P/E ratio of -1.73 and a beta of 0.82.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 2nd. The biopharmaceutical company reported ($0.80) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.02) by $0.22. The firm had revenue of $12.91 million during the quarter, compared to the consensus estimate of $15.02 million. On average, research analysts predict that Theravance Biopharma will post -3.6 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of the company. FMR LLC boosted its stake in shares of Theravance Biopharma by 10.9% during the 2nd quarter. FMR LLC now owns 10,791,863 shares of the biopharmaceutical company’s stock worth $156,698,000 after buying an additional 1,061,697 shares during the last quarter. Vanguard Group Inc. lifted its stake in Theravance Biopharma by 16.9% in the 2nd quarter. Vanguard Group Inc. now owns 5,278,969 shares of the biopharmaceutical company’s stock valued at $76,651,000 after purchasing an additional 763,854 shares during the last quarter. BlackRock Inc. lifted its stake in Theravance Biopharma by 3.2% in the 1st quarter. BlackRock Inc. now owns 4,634,135 shares of the biopharmaceutical company’s stock valued at $94,583,000 after purchasing an additional 142,940 shares during the last quarter. Maven Securities LTD acquired a new stake in Theravance Biopharma in the 2nd quarter valued at about $20,125,000. Finally, State Street Corp lifted its stake in Theravance Biopharma by 9.0% in the 2nd quarter. State Street Corp now owns 1,256,058 shares of the biopharmaceutical company’s stock valued at $18,238,000 after purchasing an additional 103,439 shares during the last quarter. Institutional investors own 82.11% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Read More: Dual Listing What You Need to Know

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.